Merck Sharp & Dohme LLC v. Halozyme, Inc. et al. - PGR2025-00017

Order: Granting PO's Motion to Seal

EXPUNGED

ORDER Granting Petitioner’s Motion to Seal 37 C.F.R. §§ 42.14, 42.54

Order: ORDER Setting Oral Argument 37 C.F.R. § 42.70

Patent Owner's Updated Mandatory Notices

Patent Owner's Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-up Counsel

Patent Owner's Updated Power of Attorney

Patent Owner's Updated Exhibit List

EX2214 - Summers PTAB Declaration

EXPUNGED

Order: On Motion to Terminate

Corrected Declaration of James Naismith, Ph.D.

Patent Owner's Objections to Evidence

Petitioner's Request for Oral Argument

Patent Owner's Request for Oral Argument

2024 Chemistry Nobel Prize Background

Csoka, A. et al., “The Six Hyaluronidase-Like Genes in the Human and Mouse Genomes” Matrix Biology 20:499-508 (2001)

Huo, Z. et al., “Systemic and Mucosal Immune Responses to Sublingual or Intramuscular Human Papilloma Virus Antigens in Healthy Female Volunteers,” PLoS ONE 7(3):e33736 (2012)

Printz, M. et al., “Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration,” AAPS 24(6):110 (2022)

Emails re: AutoDock Vina (Sept. 9, 2025 - Oct. 27, 2025)

Im, S. et al., “Cryo-EM Structure of Human Hyaluronidase PH-20,” Proteins: Structure, Function, and Bioinformatics 93:1067-1073 (2025)

Transcript of the Deposition of Dr. Gary Cherr, Ph.D., November 12, 2025

Melanie Ann Simpson, Ph.D. Deposition Transcript

Gregory Petsko, Ph.D. Deposition Transcript

Transcript of the Deposition of Dr. James Moon, Ph.D., November 18, 2025

Declaration of James Naismith, Ph.D.

Declaration of Dr. Garnett Kelsoe

Dr. Naismith Analysis Spreadsheet

Dobson, “Principles of protein folding, misfolding and aggregation” Semin. Cell. Dev. Biol. 15(1):3-16 (2004)

Dobson, “Protein folding and misfolding” Nature. 18;426(6968):884-90 (2003)

Dobson, “Experimental investigation of protein folding and misfolding” Methods 34(1):4-14 (2004)

Chiti & Dobson, “Protein Misfolding, Functional Amyloid, and Human Disease” Annu. Rev. Biochem. 75:333–66 (2006)

Dobson, “Protein misfolding, evolution and Disease” Trends Biochem. Sci. (9):329-32 (1999)

Goldsmith & Tawfik, “Directed enzyme evolution: beyond the low-hanging fruit” Curr. Opin. Struct. Biol. 22(4):406-12 (2012)

Farber & Petsko, “The evolution of alpha/beta barrel enzymes” Trends Biochem. Sci. 15(6):228-34 (1990)

Nagano et al., “One Fold with Many Functions: The Evolutionary Relationships between TIM Barrel Families Based on their Sequences, Structures and Functions” J. Mol. Biol. 30;321(5):741-65 (2002)

Ochoa-Levya et al., “Protein Design through Systematic Catalytic Loop Exchange in the (beta/alpha)8 Fold” J. Mol. Biol. 10 387(4):949-64 (2009)

AutoDock Vina Tutorial 2011

Pal et al., “Comprehensive and Quantitative Mapping of Energy Landscapes for Protein-Protein Interactions by Rapid Combinatorial Scanning” J. Biol. Chem. 4;281(31):22378-22385 (2006)

Van Rossum et al., “Reporter-based screening and selection of enzymes” FEBS J. 280:2979-96 (2013)

Reed et al., “Use of Coefficient of Variation in Assessing Variability of Quantitative Assays” Clin. Diagn. Lab Immunol. 9(6):1235-9 (2002)

Ten Have et al., “Cloning and characterization of the cDNA encoding the PH20 protein in the European red fox Vulpes vulpes” Reprod. Fertil. Dev. 10(2):165-72 (1998)

Chowpongpang et al., “Cloning and characterization of the bovine testicular PH-20 hyaluronidase core domain” Biotechnol. Lett. 26(15):1247-52 (2004)

Fowler et al., “High-resolution mapping of protein sequence-function relationships” Nature Methods 7, 741–746 (2010)

Ringe & Petsko, “Q&A: What are pharmacological chaperones and why are they interesting?” J. Biol. 8:80 (2009)

Petsko, “Herding CATS” Sci. Transl. Med. 24;3(97):97 (2011)

Second Table Associating Citations from the ’520 Patent (EX1001) to Corresponding Citations in the ’731 Application (EX1026)

Calloni et al., “Investigating the Effects of Mutations on Protein Aggregation in the Cell” J. Biol. Chem. 10607-13 (2005)

Chiti et al., “Studies of aggregation of mutant proteins in vitro provided insights into genetics of amyloid diseases” PNAS 99:16419-26 (2002)

Chiti et al., “Rationalization of the effects of mutations on peptide and protein aggregation rates” Nature, 424:805-808 (2003)

Wang et al., “Immunogenicity of protein aggregates-Concerns and Realities” Int. J. Pharmaceutics 431:1-11, (2012)

Brachmann et al., “Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations” EMBO Journal 17:1847–59 (1998)

Poelwijk, Frank J., et al., “Empirical fitness landscapes reveal accessible evolutionary paths” Nature 445.7126 (2007): 383-386

Primakoff, P. et al., “Purification of the guinea pig sperm PH-20 antigen and detection of a site-specific endoproteolytic activity in sperm preparations that cleaves PH-20 into two disulfide-linked fragments,” Biology of Reproduction 38:921-934 (1988)

Koch, C. et al., “A Comparison of the Immunogenicity of the Native and Denatured Forms of a Protein,” APMIS 104:115-125 (1996)

Leder, L. et al., “Genuine and Apparent Cross-Reaction of Polyclonal Antibodies to Proteins and Peptides,” Eur. J. Biochem. 219:73-81 (1994)

Declaration of Jeffrey P. Kushan (Petitioner's Reply)

Murphy, K., “Janeway’s Immuno Biology,” (8th 2012), Chapters 1, 4, 8, 10, 11, 12, 15, and Appx I (Pt. 1)

Murphy, K., “Janeway’s Immuno Biology,” (8th 2012), Chapters 1, 4, 8, 10, 11, 12, 15, and Appx I (Pt. 2)

Yang, X. et al., “An Introduction to Epitope Prediction Methods and Software,” Rev. Med. Virol., 19: 77–96 (2009)

Bolland, S., “An Innate Path to Human B Cell Tolerance,” Immunity, 29(5):667-9 (2008)

Anderson, M. et al., “Projection of an Immunological Self Shadow Within the Thymus by the Aire Protein,” Science, 298(5597):1395-401 (2002)

Yewdell, J. et al., “Immunodominance in Major Histocompatibility Complex Class I-restricted T Lymphocyte Responses,” Annu. Rev. Immunol., 17:51–88 (1999)

Popova, L. et al., “Immunodominance of Antigenic Site B over Site A of Hemagglutinin of Recent H3N2 Influenza Viruses,” PLoS One, 7(7):e41895 (2012)

Gershoni, J. et al., “Epitope Mapping: The First Step in Developing Epitope-Based Vaccines,” BioDrugs, 21(3):145-56 (2007)

Rolland, M. et al., “Recognition of HIV-1 Peptides by Host CTL Is Related to HIV-1 Similarity to Human Proteins,” PLoS One, 2(9):e823 (2007)

Nelson, C. et al., “Peptides Determine the Lifespan of MHC Class II Molecules in the Antigen-Presenting Cell,” Nature, 371(6494):250-2 (1994)

Dormitzer, P. et al., “Influenza Vaccine Immunology,” Immunol Rev., 239(1):167-77 (2011)

Mantis, NJ., et al., “Secretory IgA ’ s Complex Roles in Immunity and Mucosal Homeostasis in the Gut,” Mucosal Immunol., 4(6):603-11 (2011)

Siskin, G. and Eisen, H., “Effect of Variation in Antibody-Hapten Association Constant upon the Biologic Activity of the Antibody,” J Immunol., 95(3):436-41 (1965)

Levine, B. and Levytska, V., “A Sensitive Hemagglutination Assay Method for Dinitrophenyl-Specific Antibodies. The Effect of Antibody Binding Affinity on Titers,” J Immunol., 98(3):648-52 (1967)

Fauci, A. et al., “The Relationship between Antibody Affinity and the Efficiency of Complement Fixation,” J Immunol., 105(1):215-20 (1970)

Laver, W. et al., “Epitopes on Protein Antigens: Misconceptions and Realities,” Cell 61:553-556 (1990)

Lu, X. et al., “Anti-gp160 IgG and IgA Antibodies Associated with a Large Increase in Total IgG in Cervicovaginal Secretions from Human Immunodeficiency Virus Type l-Infected Women,” Journal of Infectious Disease, 167(5):1189-92 (1993)

Kemp, T. et al., “Evaluation of Systemic and Mucosal Anti-HPV16 and Anti-HPV18 Antibody Responses from Vaccinated Women,” Vaccine, 26(29-30):3608-16 (2008)

Montefiori, D. et al., “Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials,” Journal of Infectious Disease, 206(3):431-41 (2012)

Cherr, G. et al., “The Dual Functions of GPI-Anchored PH-20: Hyaluronidase and Intracellular Signaling,” Matrix Biol., 20(8):515-25 (2001)

Martin-Deleon, “Epididymal SPAM1 and its Impact on Sperm Function” Molecular and Cellular Endocrinology 250:114-121 (2006)

Nolan et al., “The Safety of Recombinant Human Hyaluronidase PH20 in Nonclinical Models: An Overview of Toxicology, Pharmacology, and Impact of Anti-PH20 Antibodies,” Journal of Controlled Release, 374:369-383 (2024)

McCutcheon, J. et al., “HLA-B*0702 Antibody Epitopes are Affected Indirectly by Distant Antigen Residues,” Hum Immunol., 36(2):69-75 (1993)

Nobusawa, E. et al., “Comparison of Complete Amino Acid Sequences and Receptor-Binding Properties among 13 Serotypes of Hemagglutinins of Influenza A Viruses,” Virology, 182(2):475-85 (1991)

CDC on H5N1 CDC Press Release: “Highly Pathogenic Avian Influenza A (H5N1) Virus Infection Reported in a Person in the U.S.” (Apr. 1, 2024)

Zhang, H. et al., “Mouse Spam1 (PH-20) Is a Multifunctional Protein: Evidence for Its Expression in the Female Reproductive Tract,” Biol Reprod., 69(2):446-54 (2003)

Dunn, C. et al., “Transcription of the Human and Rodent SPAM1 / PH-20 Genes Initiates Within an Ancient Endogenous Retrovirus,” BMC Genomics, 6:47 (2005)

Hirsch, C. et al., “The Ubiquitylation Machinery of the Endoplasmic Reticulum,” Nature, 458(7237):453-60 (2009)

Singh, S., et al., “Solubilization and Refolding of Bacterial Inclusion Body Proteins,” Journal of Bioscience and Bioengineering 99:303-310 (2005)

Li, M. et al., “Importance of Glycosylation and Disulfide Bonds in Hyaluronidase Activity of Macaque Sperm Surface PH-20,” J Androl., 23(2):211-9 (2002)

Rodriguez, L. et al., “Foot and mouth disease virus vaccines,” Vaccine 27:D90-D94 (2009)

Redwood, A. et al., “Viral Vectored Immunocontraception: Screening of Multiple Fertility Antigens using Murine Cytomegalovirus as a Vaccine Vector,” Vaccine, 25(4):698-708 (2007)

Russell, M. et al., “Complement-Fixing Properties of Human IgA Antibodies. Alternative Pathway Complement Activation by Plastic-Bound, but not Specific Antigen-Bound, IgA,” Scand J Immunol., 30(2):175-83 (1989)

Nikolova E. et al., “All Forms of Human IgA Antibodies Bound to Antigen Interfere with Complement (C3) Fixation Induced by IgG or by Antigen Alone,” Scand J Immunol., 39(3):275-80 (1994)

Goodey, N. et al., “Allosteric Regulation and Catalysis Emerge via a Common Route,” Nat Chem Biol. 4(8):474-82 (2008)

Petitioner's Reply

Petitioner's Fourth Motion to Seal

Petitioner's Supplemental Brief in Opposition to Patent Owner's Motion to Terminate

Petitioner's Supplemental Brief in Opposition to Patent Owner's Motion to Terminate

Patent Owner's Fifth Motion to Seal

Patent Owner's Brief on Testimony of Ms. Kelly Grez

Petitioner's Updated Exhibit List

Deposition Transcript of Kelly Grez

Errata to Deposition Transcript of Kelly Grez

Patent Owner's Notice of Grez Deposition

Order: Granting Petitioner's Motion to Seal

Petitioner's Third Motion to Seal

Declaration of Kelly Grez – Protective Order Material

Declaration of Kelly Grez

Petitioner's Updated Exhibit List

Patent Owner's Motion to Terminate (PUBLIC - UPDATED REDACTIONS)

Order Conduct of the Proceedings

Order: Granting Petitioner's Motion to Seal

ORDER Granting Patent Owner’s Motion to Seal 37 C.F.R. §§ 42.14, 42.54

Patent Owner's Reply in Support of Motion to Terminate (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

Patent Owner's Third Motion to Seal

Patent Owner's Reply in Support of Motion to Terminate (PUBLIC - REDACTED)

Order: ORDER Conditionally Granting Patent Owner’s Motion to Seal 37 C.F.R. §§ 42.14, 42.54

MSD Netherlands Capital B.V., Preliminary Prospectus Supplement (May 14, 2024)

Merck & Co., Inc., Form 8-K (Nov. 4, 2009

Jennifer_Zachary WD_Redacted – Protective Order Material

Merck & Co., Inc. Subsidiaries (Dec. 31, 2024

State of New Jersey, Certificate of Long Form Standing with Officers and Directors, Merck & Co., Inc. (Feb. 18, 2026)

Press Release: “Merck and Schering-Plough to Merge” (Mar. 9, 2009)

State of New Jersey, Certificate of Long Form Standing with Officers and Directors, Merck Sharp & Dohme LLC (Feb. 18, 2026)

Company Statement: “Merck Sues Merck KGaA, Darmstadt, Germany for Improper Use of “Merck”” (Jan. 15, 2016)

ZacharyJennifer ADP_Redacted – Protective Order Material

Table Comparing the Boards of Directors for Merck & Co., Inc. and Merck Sharp & Dohme LLC

Merck & Co., Inc., Form 851 – Affiliations Schedule for Tax Year Ending Dec. 31, 2024

Petitioner's Updated Exhibit List

Petitioner's Motion to Seal

Petitioner's Opposition to Patent Owner's Motion to Terminate

Petitioner's Opposition to Patent Owner's Motion to Terminate

Patent Owner's Updated Exhibit List

EX2401 - E-mail (PUBLIC - REDACTED)

EX2446 - Amicus Brief

EX2447 - IPO Board of Directors

EX2448 - ChIPs - Speaker Details

EX2449 - LinkedIn

EX2450 - OED PTO Form 158

EX2451 - Employment Letter

EX2452 - 2025-09-30 Merck Co SEC FORM 13F-HR

EX2453 - 2025-09-30 MSD SEC FORM 13F-NT

EX2454 - Merck Co June 2025 Form 10-Q

EX2456 - Merck 2024 Form 10K Exhibit 24.1

EX2457 - Sarbanes-Oxley Act 2002

EX2458 - Merck Co Bio

EX2459 - NJ Rules of Professional Conduct

EX2460 - MSD Bio

EX2461 - OED Search

EX2462 - 2024 MSD LLC Schedule 13D

EX2463 - 2025 Merck Schedule 14A Proxy Statement

EX2464 - SEC Form 13F

EX2465 - Merck OED Search

EX2466 - Merck Form 8K

EX2467 - Merck Form 8K Exhibit 99.1 - Press Release

EX2468 - Exhibit 99.2 to Form 8-K, Merck & Co. Inc., February 3, 2026

Patent Owner's Updated Exhibit List

Patent Owner's Second Motion to Seal

Patent Owner's Motion to Terminate (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

Patent Owner's Motion to Terminate (PUBLIC - REDACTED)

ORDER Conduct of the Proceedings 37 C.F.R. § 42.5

EX 3002

Order: Denying Patent Owners Motion for Additional Discovery 37 C.F.R. sec. 42.51

Ex. 3001 Attorney Correspondence

Order: Conduct of Proceeding

Order: Granting Motion to Seal

Petitioner's Opposition to Patent Owner's Motion for Additional Discovery

MERCK_PGR00355 - PTAB-PGR2021-00036-1 Merck- Genentech PGR

MERCK_PGR00458 - PTAB-PGR2021-00036-16 Merck- Genentech PGR

MERCK_PGR00462 - RE_ 2_25-cv-03179-ES-JRA_ HALOZYME, INC. v. MERCK SHARP & DOHME CORP.

MERCK_PGR00094 - DNJ-2-25-cv-03179 Stipulation to Substitute Parties

MERCK_PGR00090 - DNJ-2-25-cv-03179 2025-07-14 [019] Corporate Disclosure Statement

EX2069 - Simpson CV

EX2071 - Petsko CV

EX2072 - Cherr Declaration

EX2073 - Cherr CV

EX2074 - Moon Declaration

EX2075 - Moon CV

EX2076 - Hecht Deposition Transcript

EX2077 - Park Deposition Transcript 2025-08-07

EX2078 - Park Deposition Transcript 2025-08-21

EX2079 - Koehl 1999

EX2080 - Pommié 2004

EX2082 - Kyte and Doolittle 1982

EX2083 - Assay Guidance Manual (Part 1 of 6)

EX2083 - Assay Guidance Manual (Part 2 of 6)

EX2083 - Assay Guidance Manual (Part 3 of 6)

EX2083 - Assay Guidance Manual (Part 4 of 6)

EX2083 - Assay Guidance Manual (Part 5 of 6)

EX2083 - Assay Guidance Manual (Part 6 of 6)

EX2084 - The Central Role of Enzymes as Biological Catalysts

EX2085 - French 1983

EX2086 - El-Safory 2010

EX2087 - Lu 2025

EX2088 - Stern & Cóska 2000

EX2089 - Gmachl 1993

EX2090 - Gmachl-Kreil 1993

EX2091 - Davies 1995

EX2092 - Markovic-Housley 2000

EX2093 - Baker (US8343487B2)

EX2094 - MULTIDROP 384 Liquid Handling Device Manual 2008

EX2096 - Frost 1997

EX2097 - Bookbinder (US20050260186A1)

EX2098 - Delpech 1995

EX2099 - Takahashi 2003

EX2100 - Vines 2001

EX2101 - Wassarman 1999

EX2102 - Yudin 1988

EX2103 - Tollner 2012

EX2104 - Visconti 1998

EX2105 - Wassarman 2001

EX2106 - Bailey 2010

EX2107 - Sabeur 1997

EX2108 - Hunnicutt 1996

EX2109 - Tollner 2008

EX2110 - Tollner 2009

EX2111 - Yudin BOR 2005

EX2112 - Yudin 2005

EX2113 - Tollner 2011

EX2114 - Frayne 1999

EX2115 - Yanagimachi 1975

EX2116 - Chamley 2007

EX2117 - Kremer 1992

EX2118 - Primakoff 1983

EX2119 - Myles and Primakoff 1984

EX2120 - Chan 1999

EX2121 - Ganesan 2010

EX2122 - Mestecky 1999

EX2126 - Suri 2005

EX2127 - Morrow 2011

EX2128 - Hussain 2005

EX2129 - Veazey 2003

EX2130 - Baloglu 2009

EX2131 - Suarez 2006

EX2132 - Cauci 2005

EX2133 - Flori 2007

EX2134 - Mestecky 2010

EX2135 - Kim 2005

EX2136 - Lardner 2001

EX2137 - Lipman 2005

EX2138 - Rhee 2012

EX2139 - Lycke 2012

EX2140 - Rudin 1998

EX2141 - Wu 2000

EX2142 - Russell 2002

EX2143 - Uppada 2011

EX2145 - Gallichan 1995

EX2146 - Johansson 1998

EX2147 - Bergquist 1997

EX2148 - Neto 2009

EX2149 - Rhorer 2009

EX2150 - Mielcarek 2000

EX2151 - Houghton 2004

EX2152 - Wan 2007

EX2153 - Dieude 2009

EX2154 - Oliver 2003

EX2155 - Trentham 1977

EX2156 - Courtenay 1980

EX2157 - Tomita 2011

EX2158 - Zhang 2012

EX2159 - Zeitlin 1996

EX2160 - Sherwood 1996

EX2161 - Veselinovic 2012

EX2162 - Schweitzer 2008

EX2163 - Gregory Petsko - National Science and Technology Medals Foundation

EX2164 - Protein Structure and Function (Part 1 of 4)

EX2164 - Protein Structure and Function (Part 2 of 4)

EX2164 - Protein Structure and Function (Part 3 of 4)

EX2164 - Protein Structure and Function (Part 4 of 4)

EX2165 - Wei (US20100143457A1)

EX2166 - Petsko Patent Analysis Data

EX2167 - Huang 2007

EX2168 - Gregory A. Petsko - American Academy of Arts and Sciences

EX2169 - Query Input and database selection - BlastTopics 0.1.1 documentation

EX2170 - Chain and Duthie 1940

EX2171 - Tollner 2004

EX2172 - Yudin 2001

EX2173 - Yudin 1999

EX2174 - Park 2068

EX2175 - Park 2069

EX2176 - Park 2070

EX2177 - E-mail

EX2178 - 1LOH pdb file

EX2179 - 1FCV pdb file

EX2180 - 2PE4 pdb file

EX2181 - 8SMN pdb file

EX2182 - E324A

EX2183 - E324D

EX2184 - E324H

EX2185 - E324M

EX2186 - E324N

EX2187 - E324R

EX2188 - E324S

EX2189 - N47A_N219_E324D Swiss Model

EX2190 - N47A_N131A_E324D Swiss Model

EX2191 - PH20

EX2192 - N131A_N219A_E324D Swiss Model

EX2193 - N47A_N131A_N219A_E324D Swiss Model

EX2194 - N47A_N219A_E324N Swiss Model

EX2195 - N47A_N131A_E324N Swiss Model

EX2196 - N47A_N131A_N219A_E324N Swiss Model

EX2197 - N131A_N219A_E324N Swiss Model

EX2198 - N47A_N219A_E324R Swiss Model

EX2199 - N47A_N131A_E324R Swiss Model

EX2200 - N47A_N131A_N219A_E324R Swiss Model

EX2201 - N131A_N219A_E324R Swiss Model

EX2202 - Orangutan E324D

EX2203 - Orangutan E324N

EX2204 - Orangutan E324R

EX2205 - Chimpanzee E324D

EX2206 - Chimpanzee E324N

EX2207 - Chimpanzee E324R

EX2208 - Gibbon E324D

EX2209 - Gibbon E324N

EX2210 - Gibbon E324R

EX2070 - Petsko Declaration

EX2068 - Simpson Declaration

Patent Owner's Response

EX2400 - Merck Co - 10Q - 11-05-2025

EX2402 - MERCK_PGR00006 - Sidley MSA (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2403 - MERCK_PGR00056 - Dechert MSA (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2404 - MERCK_PGR00467 - Mark Stewart Offer Letter (CONFIDENTIAL - PROTECTIVE ORDER MA

EX2405 - MERCK_PGR00052 - Hecht Engagement Letter (CONFIDENTIAL - PROTECTIVE ORDER MATE

EX2406 - MERCK_PGR00086 - Park Engagement Letter (CONFIDENTIAL - PROTECTIVE ORDER MATER

EX2407 - Executive Team - MSD

EX2408 - Executive Team - Merck

EX2409 - Board of Directors - MSD

EX2410 - Board of Directors - Merck

EX2411 - Contact Us - MSD

EX2412 - Contact Us - Merck

EX2413 - Who We Are - MSD

EX2414 - Who We Are - Merck

EX2415 - Merck Co - 10k - year 2024

EX2416 - USPTO OED Practitioner Search - Mark Stewart registration

EX2417 - IPR2024-00240 Petition

EX2418 - IPR2024-00622 Petition

EX2419 - IPR2024-00623 Petition

EX2420 - IPR2024-00624 Petition

EX2421 - IPR2024-00625 Petition

EX2422 - IPR2024-00647 Petition

EX2423 - IPR2024-00648 Petition

EX2424 - IPR2024-00649 Petition

EX2425 - IPR2024-00650 Petition

EX2426 - MERCK_PGR00035 - 20250813 Payment Remittance (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2427 - MERCK_PGR00042 - Dechert T360 Halozyme (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2428 - MERCK_PGR00045 - FW_ Attn_ Accounts Receivable Dept (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2429 - MERCK_PGR00049 - Halozyme - 202000447 - Invoices (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2430 - MERCK_PGR00465 - Mark Stewart Payroll Statement (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2431 - MERCK_PGR00001 - Ginkel Organization Screen Shot (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2432 - MERCK_PGR00002 - Lally Organization Screen Shot (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2433 - MERCK_PGR00003 - Majchrzak Organization Screen Shot (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2434 - MERCK_PGR00004 - Stewart Organization Screen Shot (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2435 - MERCK_PGR00005 - Su Organization Screen Shot (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2436 - MERCK_PGR00036 - 20250903 Payment Remittance_Redacted (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2437 - MERCK_PGR00037 - 20251001 Payment Remittance_Redacted (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2438 - MERCK_PGR00038 - 20251203 Payment Remittance_Redacted (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2439 - MERCK_PGR00040 - 20251215 Payment Remittance_Redacted (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2440 - MERCK_PGR00046 - PAYMENT REMITTANCE DETAIL (Oct 2025) (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2441 - MERCK_PGR00047 - PAYMENT REMITTANCE DETAIL (Sep 2025) (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2442 - MERCK_PGR00048 - Invoice IN00125072310 Review History (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2443 - MERCK_PGR00050 - Invoices 5_1_2024-12_22_2025_2 of 3 (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2444 - MERCK_PGR00051 - Invoices 5_1_2024-12_22_2025_3 of 3 (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

EX2445 - Merck Co - Bylaws

EX2401 - E-mail (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

Patent Owner's Motion to Seal

Patent Owner's Motion for Additional Discovery (CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)

Patent Owner's Motion for Additional Discovery (PUBLIC - REDACTED)

Notice of Joint Stipulation to Modify Due Dates

AMENDED SCHEDULING ORDER

Patent Owner's Updated Mandatory Notices

Notice of Joint Stipulation to Modify Due Date 1

Notice of Intent to Designate Sue Wang as Backup Counsel

Declaration of Sue Wang

Notice of Intent to Designate Brian Goldberg as Backup Counsel

Declaration of Brian Goldberg

Notice of Intent to Designate Katherine Helm as Backup Counsel

Declaration of Katherine Helm

Petitioner's Updated Exhibit List

Petitioner's Updated Mandatory Notice

Petitioner's Updated Power of Attorney

Petitioner's Objections to Evidence

Patent Owner's Objections to Evidence

General Order: Related Matters Updates

DECISION Granting Institution of Post-Grant Review 35 U.S.C. § 324

SCHEDULING ORDER

Patent Owner's Updated Power of Attorney

Patent Owner's Updated Mandatory Notices

Patent Owner's Sur-Reply to Petitioner's Reply to Patent Owner's Preliminary Response

Patent Owner's Updated Mandatory Notices

Petitioner's Reply in Support of Petition for Post Grant Review

Director Discretionary Decision: Refer

Petitioner's Updated Mandatory Notices

Patent Owner's Updated Power of Attorney

Patent Owner's Updated Mandatory Notices

EX2007 - Gifre 2017

EX2008 - Recombinant Drugs - Smithsonian Institution

EX2009 - Naz 2011

EX2010 - Primakoff 1988

EX2011 - Guinea Pig - Merriam-Webster 2010

EX2012 - Nature 2012

EX2013 - Lin 1993

EX2016 - Pils 2005

EX2064 - PGR2025-00053 Petition

EX2065 - PGR2025-00053 EX1003 - Hecht Declaration

EX2015 - USP7872107 File History (Part 1 of 3)

EX2015 - USP7872107 File History (Part 2 of 3)

EX2015 - USP7872107 File History (Part 3 of 3)

EX2055 - Triggs-Raine Declaration

Patent Owner's Preliminary Response

Petitioner's Reply to Patent Owner's Discretionary Denial Brief

United States District Court – National Judicial Caseload Profile

Table Showing Outcomes of Disputed Motions to Stay Pending IPRs in DNJ

News Release: "Halozyme Raises 2025 Financial Guidance Ranges and Reports Strong First Quarter 2025 Results"

News Release: "Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware"

Halozyme Therapeutics, Inc. Q1 2025 Earnings Call Transcript (May 6, 2025)

Patent Owner's Updated Power of Attorney

Patent Owner's Updated Mandatory Notices

EX2002 - Triggs-Raine CV

EX2003 - Disclaimer

EX2004 - Fierce Pharma

EX2005 - LinkedIn Profiles

EX2018 - Duterme 2009

EX2019 - Atmuri 2008

EX2020 - Hemming 2008

EX2021 - Miller 2008

EX2022 - Kaneiwa 2010

EX2023 - PGR2025-00004 Petition

EX2024 - PGR2025-00003 Petition

EX2025 - PGR2025-00009 Petition

EX2026 - PGR2025-00006 Petition

EX2027 - PGR2025-00030 Petition

EX2028 - PGR2025-00024 Petition

EX2029 - PGR2025-00004 EX1003 - Hecht Declaration

EX2030 - PGR2025-00003 EX1003 - Hecht Declaration

EX2031 - PGR2025-00009 EX1003 - Hecht Declaration

EX2032 - PGR2025-00006 EX1003 - Hecht Declaration

EX2033 - PGR2025-00030 EX1003 - Hecht Declaration

EX2034 - PGR2025-00024 EX1003 - Hecht Declaration

EX2035 - Lokeshwar 2002

EX2036 - PGR2025-00033 EX1003 - Hecht Declaration

EX2037 - PGR2025-00033 Petition

EX2038 - PGR2025-00039 EX1003 - Hecht Declaration

EX2039 - PGR2025-00039 Petition

EX2046 - 2023 Pharma 50

EX2047 - Merck Financial Results

EX2048 - Products List - Merck.com

EX2050 - Merck Market Cap Nasdaq

EX2051 - Halozume Market Cap Nasdaq

EX2052 - Halozyme News Revenue

EX2053 - Halozyme - Commercial Products

EX2054 - Halozyme About Us

EX2056 - PGR2025-00042 Petition

EX2057 - PGR2025-00042 EX1003 - Hecht Declaration

EX2058 - District Court Complaint

EX2059 - Alteogen announces amendment to license agreement with MSD

EX2060 - PGR2025-00046 Petition

EX2061 - PGR2025-00046 EX1003 - Hecht Declaration

EX2062 - PGR2025-00050 Petition

EX2063 - PGR2025-00050 EX1003 - Hecht Declaration

Patent Owner Discretionary Denial Brief

EX2001 - Triggs-Raine Declaration ISO Patent Owner Discretionary Denial Brief

EX2006 - Sequence Listing

Patent Owner's Updated Mandatory Notices

Petitioner's Updates to Mandatory Notices

Patent Owner's Updated Mandatory Notices

Petitioner's Updates to Mandatory Notices

Patent Owner's Updated Mandatory Notices

Order: Granting Petitioner's Motions for Pro Hac Vice Admission of Leif E. Peterson, II - 37 CFR 42.10

Petitioner's Motion for Pro Hac Vice Admission of Leif E. Peterson, II

Declaration of Leif E. Peterson, II

Patent Owner's Updated Mandatory Notices

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

Patent Owner's Updated Mandatory Notices

Patent Owner's Updated Mandatory Notices

Petitioner's Updates to Mandatory Notices

Patent Owner's Power of Attorney

Patent Owner's Mandatory Notices

U.S. Patent No. 12,110,520

File History of U.S. Patent No. 12,110,520 Part 1

File History of U.S. Patent No. 12,110,520 Part 2

U.S. Patent No. 7,767,429

Chao, Structure of Human Hyaluronidase-1 (2007)

WO/2010/077297, published July 8, 2010

Stern, The Hyaluronidases: Their Genomics, Structures, & Mechanisms (2006)

Jedzrejas, Structures of Vertebrate Hyaluronidases (2005)

Zhang, Hyaluronidase Activity of Human Hyal1 (2009)

Arming, In vitro Mutagenesis of PH-20 Hyaluronidase from Human Sperm (1997)

Bordoli, Protein Structure Homology Modeling Using SWISSMODEL (2008)

Frost, Recombinant Human Hyaluronidase (rHuPH20) (2007)

Brandon & Tooze, Introduction to Protein Structure (1999) Part 1

Brandon & Tooze, Introduction to Protein Structure (1999) Part 2

Steipe, Consensus-Based Engineering of Protein Stability (2004)

Green, Computer Graphics, Homology Modeling, and Bioinformatics (2010)

Chica, Semi-rational Approaches to Engineering Enzyme Activity (2005)

Hardy, Assessment of Contraceptive Vaccines Based on Recombinant Mouse Sper

Pomering, Restricted Entry of IgG (2002)

Baba, Mouse Sperm Lacking Cell Surface Hyaluronidase PH-20 (2002)

Primakoff, Reversible Contraceptive Effect of PH-20 Immunization (1997)

Tung, Mechanism of Infertility in Male Guinea Pigs Immunized with Sperm

Rosengren, Recombinant Human PH20 (2018)

U.S. Patent No. 9,447,401

U.S. Patent Application No. 13/694,731

Gmachl, The Human Sperm Protein PH-20 Has Hyaluronidase Activity (1993)

Sills, "Retraction," Science, 319:569 (2008)

Yue, Loss of Protein Structure Stability as a Major Causative Factor (2005)

Wang & Moult, SNPs, Protein Structure, and Disease (2001)

Markovic-Housley, Crystal Structure of Hyaluronidase (2000)

"Negative Results," Nature: Editorials, 453:258 (2008)

Lins, Analysis of Accessible Surface of Residues in Proteins (2003)

Hayden, Chemistry: Designer Debacle (2008)

Benkert, Toward the Estimation of the Absolute Quality (2010)

Schwede, SWISS-MODEL: An Automated Protein Homology-Modeling Server (2003)

Alberts, Molecular Biology of the Cell, Chapter 3 (2007)

He, NMR Structures of Two Designed Proteins with High Sequence Identity

Alexander, A Minimal Sequence Code for Switching Protein Structure (2009)

Ruan, Design & Characterization of a Protein Fold Switching Network (2023)

Sievers, Fast, Scalable Generation of High-Quality Protein (2011)

Mihel, PSAIA – Protein Structure and Interaction Analyzer (2008)

Redline Comparison of the ’731 and ’520 Specifications

Beasley & Hecht, Protein Design: The Choice of de Novo Sequences (1997)

Xiong, Periodicity of Polar and Nonpolar Amino Acids (1995)

Hayden, Key Protein-Design Papers Challenged (2009)

KEGG, DRUG: Hyaluronidase (human recombinant)

Pace & Scholtz, A Helix Propensity Scale (1998)

U.S. Patent Application No. 61/631,313

U.S. Patent Application No. 61/796,208

Hom_pre2011

Hom_pre2011_header

Hom_pre2011_header_clean

Hom_pre2011.fasta

Ph20_pre2011.aln-clustal_num

Ph20_pre2011 Alignment html

Leisola & Turunen, Protein Engineering: Opportunities and Challenges (2007)

Hecht, De Novo Proteins from Designed Combinatorial Libraries (2004)

Rosengren, Clinical Immunogenicity of rHuPH20 (2015)

Collection of BLAST Webpages from the Internet Archive

Collection of Clustal Omega Webpages from the Internet Archive

Collection of SWISS-MODEL Webpages from the Internet Archive

Collection of PyMol Webpages from the Internet Archive

Swiss Model Printout of PH20 Model

Swiss Model Printout of PH20 Model with E324D Mutation

Swiss Model Printout of PH20 Model with E324N Mutation

Swiss Model Printout of PH20 Model with E324R Mutation

Swiss Model Printout of PH20 Model with E324A Mutation

Swiss Model Printout of PH20 Model with E324H Mutation

Swiss Model Printout of PH20 Model with E324S Mutation

Declaration of Dr. Michael Hecht

Declaration of Dr. Sheldon Park

Table Associating ’520 Patent to Corresponding ’731 Application

Declaration of Jeffrey P. Kushan

Petition for Post Grant Review of U.S. Patent No. 12,110,520

Petitioner's Power of Attorney